Results 81 to 90 of about 10,512 (252)

Arrested Puberty in a Young Adult With a Macroprolactinoma: Case Report and Literature Review

open access: yesCase Reports in Endocrinology, Volume 2025, Issue 1, 2025.
Prolactinoma is the most common pituitary tumor, with clinical presentations varying according to sex, age of onset, tumor size, and prolactin (PRL) levels. These tumors are rare in the pediatric and adolescent populations. Hyperprolactinemia leads to hypogonadotropic hypogonadism, resulting in reproductive, metabolic, sexual, and skeletal consequences
Sánchez M.   +4 more
wiley   +1 more source

Somatic SF3B1 hotspot mutation in prolactinomas. [PDF]

open access: yes, 2020
The genetic basis and corresponding clinical relevance of prolactinomas remain poorly understood. Here, we perform whole genome sequencing (WGS) on 21 patients with prolactinomas to detect somatic mutations and then validate the mutations with digital ...
Cheng, Sen   +24 more
core  

Male, Female, Other: Transgender and the Impact in Primary Care [PDF]

open access: yes, 2016
Transgender includes patients at various stages of their journey. It is important that providers care for transgender patients with a culturally sensitive approach, awareness, and competent skill. There are new terms to learn.
Markwick, Laura
core   +2 more sources

Bone mineral density and bone turnover in hyperprolactinaemia of various origins [PDF]

open access: yes, 2007
Introduction: Osteopoenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by an increased risk of fracture. There are no data on the bone effects of functional hyperprolactinaemia.
Bolanowski, Marek   +3 more
core   +1 more source

Tractography‐Based Automated Identification of Retinogeniculate Visual Pathway With Novel Microstructure‐Informed Supervised Contrastive Learning

open access: yesHuman Brain Mapping, Volume 45, Issue 17, December 1, 2024.
We present a novel deep learning framework, DeepRGVP, to enable fast and accurate identification of the RGVP from dMRI tractography data. We design a novel microstructureinformed supervised contrastive learning method to determine positive and negative pairs.
Sipei Li   +17 more
wiley   +1 more source

Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas

open access: yesImmunity, Inflammation and Disease, Volume 12, Issue 12, December 2024.
ABSTRACT Background The overwhelming majority of pituitary tumors consist of pituitary adenomas (PAs), which have recently also been termed pituitary neuroendocrine tumors (PitNETs). Clinically significant PAs occur in approximately one in every 1000 individuals, while other types of pituitary tumors, such as craniopharyngiomas and pituicytomas, are ...
Dingkai Xu, Ling Wang, Maohua Zheng
wiley   +1 more source

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists [PDF]

open access: yes, 2010
Despite the fact that consensus guidelines recommend long-term dopamine agonist (DA) therapy as a first-line approach to the treatment of small prolactinoma, some patients continue to prefer a primary surgical approach.
A Antonini   +63 more
core   +2 more sources

Visual morbidity in macroprolactinoma: A retrospective cohort study

open access: yesClinical Endocrinology, Volume 101, Issue 6, Page 648-658, December 2024.
Abstract Objective The management of visual field damage in patients with macroprolactinomas is a major therapeutic challenge. We aimed to study the visual morbidity associated with macroprolactinoma and its outcomes following medical and surgical treatment. We aimed to identify predictors of visual recovery. Methods We retrospectively reviewed patient'
Yaron Rudman   +4 more
wiley   +1 more source

New Pituitary Adenoma Classification System to Individualise Management and Improve Long‐Term Prognosis

open access: yes
Clinical Endocrinology, Volume 102, Issue 2, Page 147-148, February 2025.
Gudmundur Johannsson   +2 more
wiley   +1 more source

The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double‐edge sword

open access: yesJournal of Cellular and Molecular Medicine, Volume 28, Issue 23, December 2024.
Abstract The metabolic syndrome (MetS) is a clustering of abdominal obesity, hypertension, hyperglycaemia, hypertriglyceridemia and low high‐density lipoprotein (HDL) level. MetS development is affected by endocrine hormones such as prolactin (PRL) hormone which induce insulin resistance and central obesity because PRL is implicated in the pathogenesis
Ayah Talal Zaidalkilani   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy